



10/14

25.1.24.03

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231

On January 10, 2003
By: Charles Angelis R

PATENT

Attorney Docket No.: 14538A-005810US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RONALD H. REEDER *et al.*

Examiner: Misook Yu

Application No.: 09/932,678

Art Unit: 1642

Filed: August 16, 2001

For: HUMAN RRN3 AND
COMPOSITIONS AND METHODS
RELATING THERETO

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed August 12, 2002, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Kindly amend the specification as follows. An Appendix setting forth the amended portions of the specification showing all changes is provided as required under 35 U.S.C. § 1.121(b).

Please delete the paragraph beginning at page 12, line 13, and insert the following:

The term "immunologically cross-reactive" means that a polypeptide, fragment, derivative or analog is capable of competitively inhibiting the binding of an antibody to its antigen.

Please delete the paragraph beginning at page 22, line 31, and insert the following: